Prelude Therapeutics Q2 FY26 net loss narrows to $13.92 million; revenue turns to $5.7 million

Reuters2026/08/11 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prelude Therapeutics posted Q2 revenue of $5.7 million, swinging from no revenue a year earlier; net loss narrowed to $13.9 million, or $0.14 per share.
R&D expense fell to $16.1 million from $25.8 million, on lower SMARCA2 trial costs after a 2025 pause and a workforce reduction.
Cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million at June 30, with runway expected into Q2 2028.
Plans to initiate a Phase 1 study of KAT6A degrader PRT13722 in HR+ breast cancer in Q4 2026, pending IND clearance; PRT12396 Phase 1 enrollment continues in PV and MF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807051) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prelude Therapeutics Q2 FY26 net loss narrows to $13.92 million; revenue turns to $5.7 million

You may also like

Crypto prices